Literature DB >> 3091919

Glucose metabolism in fibroblasts from patients with erythrocyte hexokinase deficiency.

M Magnani, L Chiarantini, V Stocchi, M Dachà, G Fornaini.   

Abstract

Four different hexokinase (HK) isoenzymes are distributed in different proportions in human tissues. Fibroblasts contain HK type I as the predominant glucose phosphorylating activity, the same isoenzyme that predominates in red blood cells (RBC). We have established cell lines from two patients homozygous for RBC HK deficiency but carrying different mutations. In one case (HK-Melzo) the residual RBC enzyme shows a marked heat instability but possesses normal kinetic and regulatory properties; in the other (HK-Napoli), the enzyme is characterized by an increased Ki for glucose-1,6-diphosphate. These properties are also retained by the fibroblasts' hexokinase. Glucose utilization by cultured fibroblasts from these patients was markedly reduced in the cell lines where HK deficiency was more pronounced. However, cells with only 30% HK activity retained their full ability to utilize glucose in the hexose monophosphate pathway. This was shown to be true not only under basal conditions but also in the presence of oxidative agents such as methylene blue. Significant reduction of the ATP level was also found in HK-Melzo fibroblasts. Thus, HK deficiency is associated with reduced glucose utilization and normal hexose monophosphate shunt rates. Results previously obtained on RBC support similar conclusions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091919     DOI: 10.1007/bf01799449

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

1.  Localization of the structural genes for hexokinase-1 and inorganic pyrophosphatase on region (pter-->q24) of human chromosome 10.

Authors:  C J Chern
Journal:  Cytogenet Cell Genet       Date:  1976

2.  Selectivity of proteases as a basis for tissue distribution of enzymes in hereditary deficiencies.

Authors:  E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

3.  Solubilization, purification, and properties of rabbit brain hexokinase.

Authors:  M Magnani; G Serafini; V Stocchi; M Bossù; M Dachà
Journal:  Arch Biochem Biophys       Date:  1982-07       Impact factor: 4.013

4.  Hereditary hemolytic anemia with hexokinase deficiency. Role of hexokinase in erythrocyte aging.

Authors:  W N Valentine; F A Oski; D E Paglia; M A Baughan; A S Schneider; J L Naiman
Journal:  N Engl J Med       Date:  1967-01-05       Impact factor: 91.245

5.  Human erythrocyte hexokinase deficiency: a new variant with abnormal kinetic properties.

Authors:  M Magnani; V Stocchi; F Canestrari; M Dachà; P Balestri; M A Farnetani; D Giorgi; A Fois; G Fornaini
Journal:  Br J Haematol       Date:  1985-09       Impact factor: 6.998

6.  Multiple forms of human red blood cell hexokinase. Preparation, characterization, and age dependence.

Authors:  V Stocchi; M Magnani; F Canestrari; M Dachà; G Fornaini
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

7.  Regulatory properties of human erythrocyte hexokinase during cell ageing.

Authors:  G Fornaini; M Magnani; A Fazi; A Accorsi; V Stocchi; M Dachà
Journal:  Arch Biochem Biophys       Date:  1985-06       Impact factor: 4.013

8.  Hereditary disorders of red cell enzymes in the Embden-Meyerhof pathway.

Authors:  S Miwa
Journal:  Am J Hematol       Date:  1983-06       Impact factor: 10.047

9.  Congenital nonspherocytic hemolytic anemia with an unstable hexokinase variant.

Authors:  P G Board; R Trueworthy; J E Smith; K Moore
Journal:  Blood       Date:  1978-01       Impact factor: 22.113

10.  Relationship between glucose phosphorylating activities and erythrocyte age.

Authors:  G Fornaini; M Magnani; M Dachà; M Bossú; V Stocchi
Journal:  Mech Ageing Dev       Date:  1978-10       Impact factor: 5.432

View more
  1 in total

Review 1.  The biochemical basis of mitochondrial diseases.

Authors:  H R Scholte
Journal:  J Bioenerg Biomembr       Date:  1988-04       Impact factor: 2.945

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.